PT-141 vs Tadalafil: How They Differ
PT-141 (bremelanotide) is a seven-amino-acid peptide that activates melanocortin receptors in the brain, on circuits tied to sexual desire; tadalafil is a long-acting PDE5 inhibitor that works in erectile tissue, prolonging the blood-flow signal that sexual stimulation sets off. The core difference is where each acts: PT-141 centrally, tadalafil peripherally. Tadalafil is an approved prescription medicine for erectile dysfunction with a half-life of about 17.5 hours, while the PT-141 we supply is a research compound. Here is how their mechanisms and human studies compare.
Findings
- Tadalafil’s mean half-life is 17.5 hours, measured across 237 healthy subjects in 13 pharmacology studies, which is long for a PDE5 inhibitor (2006).
- In an integrated analysis of five placebo-controlled trials in 1,112 men, 81% on the highest dose reported improved erections against 35% on placebo (2002).
- A trial of 348 men recorded 59.2% successful attempts 36 hours after tadalafil against 28.3% on placebo (2003).
- PT-141 acts on MC3 and MC4 melanocortin receptors, with MC4 receptors in the hypothalamus most relevant to its effect on desire.
- Two phase 3 trials in 1,267 premenopausal women found significant gains in sexual desire and reductions in distress against placebo over 24 weeks (2019).
What is tadalafil?
Tadalafil is a small-molecule, potent and selective inhibitor of phosphodiesterase type 5 (Brock et al., J Urol, 2002). Like other drugs in its class, it stops PDE5 breaking down cyclic GMP, the messenger that relaxes smooth muscle in erectile tissue after nitric oxide is released during sexual stimulation. What sets it apart is duration. Across 13 clinical pharmacology studies in 237 healthy subjects, it reached peak concentration at about 2 hours and then declined with a mean half-life of 17.5 hours. Food had negligible effects on absorption, and with once-daily dosing it reached steady state by day 5 (Forgue et al., Br J Clin Pharmacol, 2006).
The human trials of tadalafil
The integrated analysis of five randomised, double-blind, 12-week trials covered 1,112 men aged 22 to 82 with mild to severe erectile dysfunction of various causes. Tadalafil improved every efficacy outcome against placebo: at the highest dose, erectile function scores rose by a mean of 7.9 points, 75% of intercourse attempts were completed, and 81% of men reported improved erections against 35% on placebo. The effect held across severities, causes and ages; headache and dyspepsia were the most frequent adverse events (Brock et al., J Urol, 2002).
A dedicated trial then tested the long window. In 348 men, attempts made about 36 hours after a dose succeeded 59.2% of the time against 28.3% on placebo, and at about 24 hours 52.9% against 29.1% (Porst et al., Urology, 2003). The long half-life also made daily dosing possible: in a 12-week trial of 268 men, 84.5% and 84.6% of men on the two once-a-day doses reported improved erections against 28.3% on placebo, and about half reached scores in the no-dysfunction range (Porst et al., Eur Urol, 2006).
What is PT-141?
PT-141, or bremelanotide, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone and an agonist at the MC3 and MC4 receptors (Diamond et al., J Sex Med, 2006). It activates several melanocortin receptor subtypes, but MC4, which is concentrated in the medial preoptic area of the hypothalamus, is the most relevant. Animal work suggests it acts on presynaptic MC4 receptors there to increase dopamine release, which is linked to sexual desire (Pfaus et al., CNS Spectr, 2022). It was approved in the United States in 2019 as an on-demand injectable for acquired low sexual desire in premenopausal women (Dhillon and Keam, Drugs, 2019). Its links to its parent compound are covered in PT-141 vs Melanotan II.
The human studies of PT-141
The male studies came first. Intranasal PT-141 produced erectile responses that were statistically significant against placebo, with the first erection at about 30 minutes and a plasma half-life of about 1.9 to 2.1 hours (Diamond et al., Int J Impot Res, 2004). In a companion study, subcutaneous PT-141 produced significant erections in healthy men without visual sexual stimulation, and in men who had an inadequate response to a PDE5 inhibitor (Rosen et al., Int J Impot Res, 2004).
The phase 3 programme was in women. The two RECONNECT trials randomised 1,267 premenopausal women with hypoactive sexual desire disorder to bremelanotide or placebo for 24 weeks. Desire scores rose and desire-related distress fell significantly against placebo in each trial and in the combined analysis (Kingsberg et al., Obstet Gynecol, 2019). In the integrated safety data, nausea (40% against 1.3%), flushing and headache were the most common adverse events, and small, transient blood pressure increases appeared on ambulatory monitoring (Clayton et al., J Womens Health, 2022). Study-by-study detail is in PT-141 human studies.
How do PT-141 and tadalafil compare side by side?
| Question | PT-141 (bremelanotide) | Tadalafil |
|---|---|---|
| What is it? | Synthetic cyclic peptide, alpha-MSH analogue | Small-molecule drug |
| Size | Seven amino acids | Not a peptide |
| Where it acts | Brain: hypothalamic melanocortin receptors | Erectile tissue: PDE5 enzyme |
| Half-life in human studies | About 2 hours (intranasal) | About 17.5 hours (oral) |
| Main research area | Sexual desire and arousal | Erectile dysfunction |
| Human evidence | Phase 3 trials in women; earlier studies in men | Randomised trials in more than 1,000 men |
| Status | Research compound (one approved injectable form in the US) | Approved prescription medicine |
| Forms we supply | Lyophilised vial and nasal spray | Not supplied |
Where the two research literatures differ
- Time course: tadalafil’s research is defined by its long window, with trials built around 24 and 36 hours and daily dosing. PT-141’s studies measured responses within the first hour and an elimination half-life near two hours.
- Central versus peripheral: tadalafil works on the vascular step and depends on the nitric oxide that stimulation releases; PT-141 produced erections in healthy men without visual stimulation, which points to a central starting point.
- Outcome measures: tadalafil trials used erectile function scores and diary-recorded attempts; bremelanotide’s phase 3 trials used desire and distress scales in women.
No published trial has compared PT-141 and tadalafil directly. The same contrast with the shorter-acting PDE5 inhibitor is set out in PT-141 vs Viagra, and other research in this area sits under Sexual Health and Intimacy Research.
How is PT-141 supplied?
PT-141 comes from us as a 10 mg lyophilised vial and as the ready-mixed PT-141 Nasal Spray in 10 mg and 20 mg bottles, each press of the metered pump delivering 0.175 mL. The PT-141 reconstitution guide covers mixing a vial with bacteriostatic water and has a calculator, and How long does PT-141 last? covers storage. Certificates of analysis are on the lab reports page, and orders ship from within Canada by Canada Post Xpresspost.
PT-141 is supplied for laboratory research use only. The studies above were clinical research using pharmaceutical preparations. Tadalafil is a prescription medicine, and nothing here compares the two for personal use.
Frequently asked questions
What is the difference between PT-141 and tadalafil?
Tadalafil is a long-acting PDE5 inhibitor that prolongs the blood-flow signal in erectile tissue during sexual stimulation. PT-141 is a seven-amino-acid peptide that activates melanocortin receptors in the brain, on pathways linked to sexual desire and arousal.
How long does tadalafil last compared with PT-141?
Tadalafil’s mean half-life was 17.5 hours in healthy subjects, and a trial recorded effects 36 hours after a dose. Intranasal PT-141 had a half-life of about 1.9 to 2.1 hours in its 2004 study, with the first erection at about 30 minutes.
Is PT-141 better than tadalafil?
No head-to-head trial exists. Tadalafil’s evidence comes from erectile dysfunction trials in men, and bremelanotide’s phase 3 evidence from desire and distress scores in premenopausal women, so the two literatures answer different questions.
Has PT-141 been studied in men who do not respond to PDE5 inhibitors?
Yes. A 2004 study recorded statistically significant erectile responses to subcutaneous PT-141 in men with an inadequate response to sildenafil, a PDE5 inhibitor in the same class as tadalafil.
Where can I buy PT-141 in Canada?
Vistara Labs supplies PT-141 as a 10 mg lyophilised vial and a ready-mixed nasal spray, shipped from within Canada by Canada Post Xpresspost. See Buy PT-141 Nasal Spray in Canada for the spray.
Product details from vistaralabs.ca, October 2026. Sources: Brock GB et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002. PMID 12352386. Forgue ST et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006. PMID 16487221. Porst H et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003. PMID 12837435. Porst H et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction. Eur Urol. 2006. PMID 16766116. Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141). J Sex Med. 2006. PMID 16839319. Pfaus JG et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022. PMID 33455598. Dhillon S, Keam SJ. Bremelanotide: first approval. Drugs. 2019. PMID 31429064. Diamond LE et al. Double-blind, placebo-controlled evaluation of intranasal PT-141 in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004. PMID 14963471. Rosen RC et al. Evaluation of subcutaneously administered PT-141 in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004. PMID 14999221. Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019. PMID 31599840. Clayton AH et al. Safety profile of bremelanotide across the clinical development program. J Womens Health. 2022. PMID 35147466.
More on this: Peptides for Libido: What the Research Shows.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
